1. Home
  2. MREO vs OBA Comparison

MREO vs OBA Comparison

Compare MREO & OBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • OBA
  • Stock Information
  • Founded
  • MREO 2015
  • OBA 2024
  • Country
  • MREO United Kingdom
  • OBA Canada
  • Employees
  • MREO N/A
  • OBA N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • OBA
  • Sector
  • MREO Health Care
  • OBA
  • Exchange
  • MREO Nasdaq
  • OBA Nasdaq
  • Market Cap
  • MREO 326.1M
  • OBA 314.7M
  • IPO Year
  • MREO N/A
  • OBA 2025
  • Fundamental
  • Price
  • MREO $1.97
  • OBA $9.96
  • Analyst Decision
  • MREO Strong Buy
  • OBA
  • Analyst Count
  • MREO 5
  • OBA 0
  • Target Price
  • MREO $7.40
  • OBA N/A
  • AVG Volume (30 Days)
  • MREO 1.3M
  • OBA 27.5K
  • Earning Date
  • MREO 11-11-2025
  • OBA 01-01-0001
  • Dividend Yield
  • MREO N/A
  • OBA N/A
  • EPS Growth
  • MREO N/A
  • OBA N/A
  • EPS
  • MREO N/A
  • OBA N/A
  • Revenue
  • MREO $500,000.00
  • OBA N/A
  • Revenue This Year
  • MREO N/A
  • OBA N/A
  • Revenue Next Year
  • MREO $72.16
  • OBA N/A
  • P/E Ratio
  • MREO N/A
  • OBA N/A
  • Revenue Growth
  • MREO N/A
  • OBA N/A
  • 52 Week Low
  • MREO $1.47
  • OBA $9.93
  • 52 Week High
  • MREO $4.72
  • OBA $9.97
  • Technical
  • Relative Strength Index (RSI)
  • MREO 57.79
  • OBA N/A
  • Support Level
  • MREO $1.94
  • OBA N/A
  • Resistance Level
  • MREO $2.12
  • OBA N/A
  • Average True Range (ATR)
  • MREO 0.11
  • OBA 0.00
  • MACD
  • MREO 0.02
  • OBA 0.00
  • Stochastic Oscillator
  • MREO 62.65
  • OBA 0.00

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About OBA Oxley Bridge Acquisition Limited Class A Ordinary Shares

Oxley Bridge Acquisition Ltd is a blank check company.

Share on Social Networks: